Therapies

ASX-listed ophthalmic technology company Nova Eye Medical expects more cataract surgeons and comprehensive ophthalmologists to uptake its glaucoma canaloplasty procedure,...

Glaukos has commenced a Phase 2 clinical program for its third-generation iLink therapy designed to treat keratoconus. The ophthalmic medical...

Myopia’s prevalence has spawned all-new innovation and unexpected collaborations. One of those is a three-way company alliance promising Australian optometrists...

Luxturna has become the first gene therapy to receive government funding in Australia, in a landmark decision that will see...

Australian ophthalmology network PersonalEYES has become the nation’s first to offer a breakthrough method of measuring and combining data to...

The first SightGlass Vision myopia spectacles are starting to reach the market as EssilorLuxottica and CooperCompanies announce their joint venture...

The Therapeutic Goods Administration (TGA) has approved EIKANCE 0.01%, Australia’s first low-dose atropine eye drop for myopia progression in children...

Australian ophthalmologists have published the first independent head-to-head comparison of two leading minimally invasive glaucoma surgery (MIGS) devices, finding no...

Data from a six-year multicentre clinical trial confirms that CooperVision MiSight 1 day contact lenses provide myopia control for nearly...

Glaucoma affects an estimated 300,000 Australians but half of them don't know it. Early detection is considered vital to prevent...